Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone-induced mouse lung tumors

Experimental Lung Research

Volumn 24, Issue 4, 1998, Pages 499-521

  Sabourin, Carol L K ^a   Wang, Qian Shu ^a,d   Ralston, Sherry L ^a   Evans, Jason ^a   Coate, Jennifer ^a   Herzog, Christopher R ^b   Jones, Sandra L ^b   Weghorst, Christopher M ^a   Kelloff, Gary J ^c   Lubet, Ronald A ^c   You, Ming ^b   Stoner, Gary D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cdk4; Cyclin D1; Lung; Mouse; P16(INK4a); Rb; Tumor

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL CYCLE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; GENE AMPLIFICATION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 15644373914     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809087383     Document Type: Conference Paper

References (81)

1. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
2. Sherr CJ, Mammalian G1 cyclins. Cell. 1993;73:1059-1065.
3. 1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
4. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
5. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
6. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression versus retinoblastoma inactivation : implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA. 1994;91:7827-7831.
7. INK4a expression in primary lung cancers and cell lines. Cancer Res. 1995;55:505-509.
8. Mate JL, Ariza A, Aracil C, et al. Cyclin D1 overexpression in non-small cell lung carcinoma correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol. 1996;180:395-399.
9. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996;73:294-300.
10. Yang W-I, Chung K-Y, Shin D-H, Kim Y-B. Cyclin D1 protein expression in lung cancer. Yonsei Med J. 1996;37:142-150.
11. Said TK, Luo L, Medina D. Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclin D1 and D2 binding to cdk4. Carcinogenesis. 1995;16:2507-2513.
12. Wang Q-S, Sabourin CLK, Wang H, Stoner GD, Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis. 1996;17:1583-1588.
13. Youssef EM, Hasuma T, Morishima Y, et al. Overexpression of cyclin D1 in rat esophageal carcinogenesis model. Jpn J Cancer Res. 1997;88:18-25.
14. Bianchi AB, Fischer SM, Robles AI, Rinchik EM, Conti CJ. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene. 1993;8:1127-1133.
15. Robles AI, Conci CJ. Early Overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis. 1995;16:781-786.
16. INK4a or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 1995;55:4833-4836.
17. Sonoda Y, Yoshimoto T, Skiya T. Homozyous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 1995;11:2145-2149.
18. Rollbroker B, Waha A, Louis DN, Wiestler OD, von Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol. 1996;92:70-74.
19. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53:5535-5541.
20. INK4a proteins in cutaneous malignant melanoma. Br J Dermatol. 1996;134:269-275.
21. Zhang T, Nanney LB, Luongo C. et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997;57:169-175.
22. Sgambato A, Han EK-H, Zhang Y-J, Moon RC, Santella RM, Weinstein IB. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced mammary tumors. Carcinogenesis. 1995;16:2193-2198.
23. INK4a protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 1994;9:3375-3378.
24. INK4a expression in primary lung cancers and cell lines. Cancer Res. 1995;55:505-509.
25. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst. 1995;87:756-761.
26. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996;65:442-445.
27. INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
28. INK4a and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 1996;56:5557-5562.
29. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241:353-357.
30. Yokata J, Akiyama T, Fung Y-KT, et al. Altered expression of the retinoblastoma (Rb) gene in small-cell carcinoma of the lung. Oncogene. 1988;3:471-475.
31. Hensel CH, Hsieh C-L, Gazdar AF, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 1990;50:3067-3072.
32. Xu H-J, Hu S-X, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma prote in expression in primary non-small cell lung carcinomas. Cancer Res. 1991;51:2735-2739.
33. Xu H-J, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994;86:695-699.
34. Reissmann PT, Koga H, Takahashi R, et al. and the Lung Cancer Study Group. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene. 1993;8:1913-1919.
35. Shimizu E, Coxon A, Otterson GA, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994;9:2441-2448.
36. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 1995;55:514-517.
37. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995;55:1448-1451.
38. Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 1995;11:1843-1851.
39. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res (Suppl). 1992;52:2670s-2676s.
40. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9:875-884.
41. Stoner GD, Adam-Rodwell G, Morse MA. Lung tumors in strain A mice: application for studies in cancer chemoprevention. J Cell Biochem. 1993;17F:95-103.
42. Shimkin MB, Stoner GD. Lung tumors in mice: Application to carcinogenesis bioassay. Adv Cancer Res. 1975;21:1-58.
43. Belinsky SA, Devereux TR, Maronpot RR, Stoner GD, Anderson MW. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res. 1989;49:5305-5311.
44. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA. 1989;86:3070-3074.
45. Devereux TR, Anderson MW, Belinsky SA. Role of ras protooncogene activation in the formation of spontaneous and nitrosamme-induced lung tumors in the resistant C3H mouse. Carcinogenesis. 1991;12:299-303.
46. You M, Wang YL, Stoner GD, et al. Parental bias of K-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci USA. 1992;89:5804-5808.
47. Chen B, Liu L, Castonguay A, Maronpot RR, Anderson MW, You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl) -1-butanone induced mouse lung tumors. Carcinogenesis. 1993;14:1603-1608.
48. 1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis. 1995;16:2487-2492.
49. Goodrow TL, Storer RD, Leander KR, Prahalada SR, van Zwieten MJ, Bradley MO. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol Carcinog. 1992;5:9-15.
50. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996;17:217-223.
51. INK4a-β in mouse lung tumor cells. Oncogene. 1996;13:1885-1892.
52. INK4a in mouse lung tumors. Carcinogenesis. 1997;18:115-120.
53. Herzog CR, Chen B, Wang Y, Schut HAJ, You M. Loss of heterozygosity on chromosomes 1, 11, 12, and 14 in hybrid mouse lung adenocarcinomas. Mol Carcinog. 1996;16:83-90.
54. Re FC, Manenti G, Borrello MG, et al. Multiple molecular alterations in mouse lung tumors. Mol Carcinog. 1992;5:155-160.
55. Foley JF, Anderson MW, Stoner GD, Gaul BW, Hardisty JF, Maronpot RR. Proliferative lesions of the mouse lung: progression studies in strain A mice. Exp Lung Res. 1991;17:157-168.
56. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990;29:10351-10356.
57. INK4b genes. Oncogene. 1995;11:635-645.
58. Konecki DS, Brennand J, Fuscoe JC, Caskey CT, Chinault AC. Hypoxanthine-guanine phosphoribosyltransferase genes of mouse and Chinese hamster: construction and sequence analysis of cDNA recombinants. Nucleic Acids Res. 1982;10:6763-6775.
59. Nakayama H, Yokoi H, Fujita J. Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 1992;20:4939.
60. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM. Cold SSCP: a simple, rapid and non-radioactive method for optimized single strand conformation polymorphism analyses. Nucleic Acids Res. 1993;16:3637-3642.
61. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993;8:3447-3457.
62. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369:669-671.
63. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 1996;3:131-135.
64. Zhou P, Jiang W, Shang Y-J, et al. Antisense of cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 1995;11:571-580.
65. Nadir A, Doki Y, Han EK-H, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997;57:1569-1574.
66. Filmus J, Robles AI, Shi W, Wong MJ, Colomobo LL, Conti CJ. Induction of cyclin D1 overexpression by activated ras. Oncogene. 1994;9:3627-3633.
67. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams, JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124-2130.
68. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 1986;322:78-80.
69. Roop DR, Lowy DR, Tambourin PE, et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature. 1986;323:822-824.
70. Mitsunaga SI, Zhang SY, Ruggeri BA, et al. Positive immunohistochemical staining of p53 and cyclin D1 in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a]pyrene. Carcinogenesis. 1995;16:1629-1635.
71. Ruggeri BA, Bauer B, Zhang S-Y, Klein-Szanto AJP. Murine squamous cell carcinoma cell lines produced by a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cyl1/cyclin D1 abnormalities. Carcinogenesis. 1994;15:1613-1619.
72. DiGiovanni J, Beltran L, Rupp A, Harvey RG, Gill RD. Further analysis of c-Ha-ras mutations in papillomas initiated by several polycyclic aromatic hydrocarbons and papillomas from uninitiated, promoter-treated skin in SENCAR mice. Mol Carcinog. 1993;8:272-279.
73. INK4a in human cancer. Proc Natl Acad Sci USA. 1991;91:11045-11049.
74. INK4. Mol Carcinog. 1996;16:53-60.
75. Herzog CR, Wiseman RW, You M. Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer Res. 1994;54:4007-4010.
76. Hegi ME, Devereux TR, Dietrich WF, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994;54:6257-6264.
77. Merlo A, Herman JG, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995;1:686-692.
78. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-4530.
79. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995;55:4531-4535.
80. Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996;56:3875-3878.
81. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Hum Mutat. 1993;2:338-346.